Twitter | Pretraživanje | |
Alnylam
Alnylam is the world’s leading RNAi therapeutics company. We believe that patients living with life-threatening diseases deserve innovative new treatments.
2.216
Tweetovi
533
Pratim
11.472
Osobe koje vas prate
Tweetovi
Alnylam 12 h
Tomorrow (Thursday), we'll be sharing 4th Quarter and Full Year 2019 financial results during a LIVE webcast. A replay will be available at the link below later in the day.
Reply Retweet Označi sa "sviđa mi se"
Alnylam 3. velj
26 days until ! But for the >300 million people worldwide living w/ a , their families, friends, caregivers & healthcare professionals and those focused on developing new treatments, every day is rare disease day. Learn more about how to !
Reply Retweet Označi sa "sviđa mi se"
Alnylam 31. sij
We’re pleased to announce that we’ve received a positive opinion from the EMA () Committee for Medicinal Products for Human Use () for our investigational therapeutic for the treatment of the acute hepatic .
Reply Retweet Označi sa "sviđa mi se"
Alnylam 30. sij
Acute hepatic (AHP) refers to a family of rare, often misdiagnosed genetic diseases characterized by potentially life-threatening attacks and, for some patients, chronic debilitating symptoms that negatively impact daily functioning and quality of life.
Reply Retweet Označi sa "sviđa mi se"
Alnylam proslijedio/la je tweet
John Maraganore 29. sij
Thanks and for highlighting the story as one of the successes in the Boston/Cambridge ecosystem! There is no better place in the world to make a medicine than right here!
Reply Retweet Označi sa "sviđa mi se"
Alnylam 22. sij
Symptoms of acute hepatic (AHP) can often lead to misdiagnoses of more common conditions such as IBS, fibromyalgia, appendicitis & endometriosis. As a result, patients often remain w/o a proper diagnosis for up to 15 yrs.
Reply Retweet Označi sa "sviđa mi se"
Alnylam proslijedio/la je tweet
Global Genes 16. sij
Reply Retweet Označi sa "sviđa mi se"
Alnylam 15. sij
We're to welcome our first Co-op class of the new decade! This outstanding group of 33 co-ops and legal externs represents , and . Learn more about career development at Alnylam here:
Reply Retweet Označi sa "sviđa mi se"
Alnylam 13. sij
PH1 of a Kind is a 4-part video series for kids, about kids from around the world who have been diagnosed with primary hyperoxaluria type 1 (PH1). The videos star Isabelle, Luuk, Asha and Will and each tackles a different challenge they face living with this .
Reply Retweet Označi sa "sviđa mi se"
Alnylam 12. sij
This afternoon, we announced preliminary Q4 and full year 2019 global net product revenues and additional updates. Tune in to our live webcast tomorrow at 1:30 PM ET/10:30 AM PT to learn more. Access the webcast here:
Reply Retweet Označi sa "sviđa mi se"
Alnylam 10. sij
We're pleased to announce today that we've initiated a rolling submission of a New Drug Application (NDA) to the for lumasiran, an investigational therapeutic for the treatment of primary type 1 (PH1).
Reply Retweet Označi sa "sviđa mi se"
Alnylam 10. sij
Peggy’s life partner Dan, who is living with , inspired her to convey the puzzling challenges of the disease through an original artwork as part of the “The Art of Living with hATTR Amyloidosis” project. They discuss their story in a new Q&A.
Reply Retweet Označi sa "sviđa mi se"
Alnylam 9. sij
We're headed to San Francisco for where we'll present (and webcast) a company overview and share an update on unaudited 4th quarter and full year 2019 global net product revenues. A Q&A breakout session will follow immediately.
Reply Retweet Označi sa "sviđa mi se"
Alnylam 8. sij
People who may have the primary type 1 can talk to their doctor about Alnylam Act’s no-cost, 3rd-party genetic testing & counseling. Alnylam Act may help accelerate or confirm a PH1 diagnosis so families can make informed decisions about their health.
Reply Retweet Označi sa "sviđa mi se"
Alnylam 8. sij
New year! New role? We've got >150 open roles in the US, Europe and Asia including many in research, clinical development, clinical operations, quality, medical affairs and manufacturing. Perhaps this is YOUR moment to join a leader that is also a recognized top employer.
Reply Retweet Označi sa "sviđa mi se"
Alnylam proslijedio/la je tweet
John Maraganore 31. pro
Thrilled to see the arrival of gene silencing medicines (our therapeutics) included in this great recap of important breakthroughs in medical science in 2019 by !
Reply Retweet Označi sa "sviđa mi se"
Alnylam 2. sij
“Living a Rare Life” is the story of one family’s journey to unlock the mysteries of a life-threatening genetic called and how examining their health history across generations proved to be critical.
Reply Retweet Označi sa "sviđa mi se"
Alnylam 2. sij
As we enter the new decade, we look forward to seeing the incredible biomedical breakthroughs from our industry to come and look back with pride on our contribution to the innovations of the past decade. And is just getting started!
Reply Retweet Označi sa "sviđa mi se"
Alnylam 26. pro
Supporting patient access to innovative treatments is at the core of our Patient Access Philosophy and our head of Patient Services discusses how her team works with patients in many ways to help them navigate the evolving complexities of today’s healthcare system in a new Q&A.
Reply Retweet Označi sa "sviđa mi se"
Alnylam 21. pro
For many people, like CeCe, it can take years to be accurately diagnosed with amyloidosis. Click the link below to learn more about CeCe’s story, the signs and symptoms of this and the importance of having meaningful conversations with your doctor.
Reply Retweet Označi sa "sviđa mi se"